- Evaluation of immune checkpoint inhibitors rechallenge after immune-related adverse events in patients with cancerTang, X-R.; Li, R.; Zhao, F.; Wen, X.; Wang, Y-K.; Lv, R-X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China.Xu, Chongrui; Tu, Hai-Yan; Sun, Yueli; Li, Yang-Si; Xu, Bingfei; Wang, Binchao; Chen, Hua-Jun; Wang, Zhen; Zhou, Qing; Yang, Jinji; Yang, Qi; Wu, Yi-LongVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
- Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastasesGu, T.; Yang, H.; Shen, J.; Lin, A.; Zhang, J.; Luo, P.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
期刊论文
Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
20阅读
